Zárate A, Saucedo R

Language: Spanish
References: 20
Page: 83-86
PDF size: 89.75 Kb.

ABSTRACT

The metabolic syndrome was first described as a cluster of cardiovascular risk factors; however further studies have shown the difficulty to carry out a clinical diagnosis as well as the need for laboratory tests in order to confirm it. The study of the metabolic syndrome brought about a renewed interest in the prediabetes concept and the role of insulin resistance. It is worth noting however, that not all patients with metabolic syndrome will show insulin resistance. Currently there is no single therapy available for this syndrome, therefore we need to use multiple approaches that make assessment more cumbersome. The role of adipose tissue has received considerable attention in the research of the metabolic process; moreover a preinflammatory process and coagulation have also been associated with this syndrome. The impact of the metabolic syndrome in clinical practice remains unclear.

REFERENCES

1. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106:286-288.

2. Lakka HM, Laaksonen DE, Lakka TA. The metabolic syndrome and total and cardiovascuilar disease mortality in middle aged men. JAMA 2002;288:2709-2716.

3. Reaven GM. Banting Lectura: Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.

4. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, for The American Heart Association/National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Instituite/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-438.

5. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proponed definitions. Diabetes Care 2003;26:575-581.

6. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Mehta R, Franco A, Olaiz G, Rull JA. The metabolic syndrome: a concept hard to define. Arch Med Res 2005;36:223-231.

7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Colesterol in Adults. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.

8. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.

9. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Rev 2005;36:197-209.

10. Szapary PO, Hark LA, Burke FM. The metabolic syndrome: a new focus for lifestyle modification. Patient Care 2002;36:75-88.

11. Ascaro JF, Romero R, Real JT, Lorente RI, Martínez-Valles J, Carmena R. Abdominal obesity, insulin resistance and metabolic syndrome in a southern European population. Eur J Intern Med 2003;14:101-106.

12. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7.

13. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874.

14. McLaughlin T, Abbasi F, Lamendola C. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002;106:2908-2912.

15. Kershaw E, Flier J. Adipose tissue as an endocrine organ. J Clin EndocrInol Metab 2004;89:2548-2556.

16. Goldstein B, Sclia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004;89:2563-2568.

17. Berg A, Scherer P. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-949.

18. Scheen AJ. Management of the metabolic syndrome. Minerva Endocrinol 2004;29:31-45.

19. Ansell B. The metabolic syndrome in postmenopausal women. Contemporary Ob/Gyn 2003;48:77-83.

20. Renehan AG, Howell A. Preventing cancer, cardiovascular disease and diabetes. Lancet 2005;365:1449-1451.